The authors examined the distribution of tumor growth factor-beta (TGF-beta
) isoforms and receptors in 35 giant cell tumor (GCT) of bone in comparison
with a group of benign giant cell-containing lesions of bone, including 5
aneurysmal bone cysts, 2 cases of brown tumor of hyperparathyroidism, 3 non
ossifying fibromas, and 7 cases of giant cell reparative granuloma. The res
ults of immunohistochemical analysis of GCT showed a complete absence of TG
F-beta1 expression in both mononuclear tumor cells and giant cells. Only re
active bone present within the tumor showed an intense immunoreactivity. Tr
ansforming growth factor-beta2 and TGF-beta3 were detected in the majority
of cases (97.1% and 82.8%, respectively), whereas TGF-beta receptor type I
(TGF-beta RI) and type II (TGF-beta RII) were diffusely expressed in all ca
ses. Reverse transcription-polymerase chain reaction (RT-PCR) analysis pet-
formed on 10 GCTs with specific oligonucleotide primers demonstrated the pr
esence of mRNA transcripts for TGF-beta1, 2, 3, and for TGF-beta RI and RII
. Quantitative measurements of TGF-beta1 in conditioned media from primary
cultures of GCT showed undetectable or very low amounts of the cytokine (0-
23 pg/mL). The results of immunohistochemical analysis showed that all gian
t cell-containing lesions of bone were at least focally positive for the 3
isoform of TGF-beta, with positivity present both in osteoclast-like giant
cells and mononuclear cells, and diffusely positive for TGF-beta RI and RII
. Reverse transcription-polymerase chain reaction analysis conducted on sam
ples from 3 nonossifying fibromas and 1 giant cell reparative granuloma con
firmed the expression of the corresponding mRNA. In conclusion, according t
o the current data, GCT of bone can be distinguished from other giant cell-
containing lesions of bone on the basis of thr absence of TGF-beta1 express
ion at the protein level, which appears to be the result of posttranslation
al regulation processes.